Pharmaceuticals (Feb 2022)

Repurposing Antifungals for Host-Directed Antiviral Therapy?

  • Sebastian Schloer,
  • Jonas Goretzko,
  • Ursula Rescher

DOI
https://doi.org/10.3390/ph15020212
Journal volume & issue
Vol. 15, no. 2
p. 212

Abstract

Read online

Because of their epidemic and pandemic potential, emerging viruses are a major threat to global healthcare systems. While vaccination is in general a straightforward approach to prevent viral infections, immunization can also cause escape mutants that hide from immune cell and antibody detection. Thus, other approaches than immunization are critical for the management and control of viral infections. Viruses are prone to mutations leading to the rapid emergence of resistant strains upon treatment with direct antivirals. In contrast to the direct interference with pathogen components, host-directed therapies aim to target host factors that are essential for the pathogenic replication cycle or to improve the host defense mechanisms, thus circumventing resistance. These relatively new approaches are often based on the repurposing of drugs which are already licensed for the treatment of other unrelated diseases. Here, we summarize what is known about the mechanisms and modes of action for a potential use of antifungals as repurposed host-directed anti-infectives for the therapeutic intervention to control viral infections.

Keywords